Tempest Therapeutics, Inc. – NASDAQ:TPST
Tempest Therapeutics stock price today
$9.17
+8.32
+990.37%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 4 hours
Tempest Therapeutics stock price monthly change
-62.29%
month
Tempest Therapeutics stock price quarterly change
-62.29%
quarter
Tempest Therapeutics stock price yearly change
-82.80%
year
Tempest Therapeutics key metrics
Market Cap | 33.42M |
Enterprise value | 20.58M |
P/E | -1.08 |
EV/Sales | N/A |
EV/EBITDA | -0.41 |
Price/Sales | N/A |
Price/Book | 2.21 |
PEG ratio | -0.03 |
EPS | -1.73 |
Revenue | N/A |
EBITDA | -29.13M |
Income | -29.75M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTempest Therapeutics stock price history
Tempest Therapeutics stock forecast
Tempest Therapeutics financial statements
| Jun 2023 | 0 | -7.58M | |
|---|---|---|---|
| Sep 2023 | 0 | -6.78M | |
| Dec 2023 | 0 | -7.48M | |
| Mar 2024 | 0 | -7.90M |
| Sep 2025 | 0 | -12.51M | |
|---|---|---|---|
| Oct 2025 | 0 | -13.01M | |
| Dec 2025 | 0 | -14.18M | |
| Mar 2026 | 0 | -18.81M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 30742000 | 25.73M | 83.7% |
|---|---|---|---|
| Sep 2023 | 23987000 | 25.17M | 104.96% |
| Dec 2023 | 51603000 | 24.83M | 48.13% |
| Mar 2024 | 44378000 | 23.74M | 53.51% |
| Jun 2023 | -6.39M | -117K | 1.18M |
|---|---|---|---|
| Sep 2023 | -6.48M | 0 | 21K |
| Dec 2023 | -6.17M | -7K | 34.34M |
| Mar 2024 | -7.18M | -168K | 450K |
Tempest Therapeutics alternative data
| Aug 2023 | 19 |
|---|---|
| Sep 2023 | 19 |
| Oct 2023 | 19 |
| Nov 2023 | 19 |
| Dec 2023 | 19 |
| Jan 2024 | 19 |
| Feb 2024 | 19 |
| Mar 2024 | 17 |
| Apr 2024 | 17 |
| May 2024 | 17 |
| Jun 2024 | 17 |
| Jul 2024 | 17 |
Tempest Therapeutics other data
7.76%
-14.74%
of TPST is owned by hedge funds
896.18K
-2.17M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2022 | 3700 | 0 |
| Apr 2022 | 2118644 | 0 |
-
What's the price of Tempest Therapeutics stock today?
One share of Tempest Therapeutics stock can currently be purchased for approximately $9.17.
-
When is Tempest Therapeutics's next earnings date?
Unfortunately, Tempest Therapeutics's (TPST) next earnings date is currently unknown.
-
Does Tempest Therapeutics pay dividends?
No, Tempest Therapeutics does not pay dividends.
-
How much money does Tempest Therapeutics make?
Tempest Therapeutics has a market capitalization of 33.42M.
-
What is Tempest Therapeutics's stock symbol?
Tempest Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TPST".
-
What is Tempest Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Tempest Therapeutics?
Shares of Tempest Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Tempest Therapeutics have?
As Jul 2024, Tempest Therapeutics employs 17 workers.
-
When Tempest Therapeutics went public?
Tempest Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 12 Nov 2012.
-
What is Tempest Therapeutics's official website?
The official website for Tempest Therapeutics is tempesttx.com.
-
Where are Tempest Therapeutics's headquarters?
Tempest Therapeutics is headquartered at 7000 Shoreline Court, South San Francisco, CA.
-
How can i contact Tempest Therapeutics?
Tempest Therapeutics's mailing address is 7000 Shoreline Court, South San Francisco, CA and company can be reached via phone at +41 57988589.
Tempest Therapeutics company profile:
Tempest Therapeutics, Inc.
tempesttx.comExchange:
NASDAQ
Full time employees:
17
Industry:
Biotechnology
Sector:
Healthcare
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
7000 Shoreline Court
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001544227
ISIN: US87978U1088
CUSIP: 87978U108
